Ionis Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IONS)

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals Inc (NASDAQ:IONS) issued its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.26. The business had revenue of $164 million for the quarter, compared to analysts' expectations of $145.31 million. Ionis Pharmaceuticals had a return on equity of 38.70% and a net margin of 49.90%. The firm's quarterly revenue was up 39.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.29) EPS. View Ionis Pharmaceuticals' Earnings History.

Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Ionis Pharmaceuticals.

11 Wall Street analysts have issued 12-month price objectives for Ionis Pharmaceuticals' stock. Their forecasts range from $50.00 to $120.00. On average, they anticipate Ionis Pharmaceuticals' stock price to reach $76.60 in the next year. This suggests a possible upside of 37.3% from the stock's current price. View Analyst Price Targets for Ionis Pharmaceuticals.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ionis Pharmaceuticals.

Media stories about IONS stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Ionis Pharmaceuticals.

Ionis Pharmaceuticals saw a drop in short interest in September. As of September 30th, there was short interest totalling 10,510,000 shares, a drop of 6.7% from the August 30th total of 11,260,000 shares. Based on an average trading volume of 1,040,000 shares, the days-to-cover ratio is currently 10.1 days. Approximately 8.2% of the company's shares are sold short. View Ionis Pharmaceuticals' Current Options Chain.

Some companies that are related to Ionis Pharmaceuticals include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), UCB (UCBJF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Mylan (MYL), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG) and Teva Pharmaceutical Industries (TEVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), BlackRock (BLK), Micron Technology (MU), Alnylam Pharmaceuticals (ALNY), Gilead Sciences (GILD), Alibaba Group (BABA), Biogen (BIIB), Intercept Pharmaceuticals (ICPT), Allergan (AGN) and Celgene (CELG).

Ionis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (0.14%), Decatur Capital Management Inc. (0.05%), Envestnet Asset Management Inc. (0.04%), Gateway Investment Advisers LLC (0.03%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%) and Stephens Inc. AR (0.02%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

IONS stock was sold by a variety of institutional investors in the last quarter, including Decatur Capital Management Inc., Nisa Investment Advisors LLC, Envestnet Asset Management Inc., Zurcher Kantonalbank Zurich Cantonalbank and Stephens Inc. AR. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

IONS stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Robeco Institutional Asset Management B.V., Sumitomo Mitsui DS Asset Management Company Ltd, Coastal Investment Advisors Inc., Gateway Investment Advisers LLC, DNB Asset Management AS and Kistler Tiffany Companies LLC. View Insider Buying and Selling for Ionis Pharmaceuticals.

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IONS stock can currently be purchased for approximately $55.79.

Ionis Pharmaceuticals has a market capitalization of $7.84 billion and generates $599.67 million in revenue each year. The company earns $273.74 million in net income (profit) each year or $2.96 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe.View Additional Information About Ionis Pharmaceuticals.

The official website for Ionis Pharmaceuticals is http://www.ionispharma.com/.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.